RxDoctor Payments Data

David Chansolme, MD

Infectious Disease · Oklahoma City, OKNPI 1457343402

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.4% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Gilead at 27.6% of the total. 2025 is the largest year on record at $667, 2.9 times the $233 reported in 2019.

$2,313in general payments, 2019–2025

Across 115 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$638
  • Viiv Healthcare Company$568
  • Insmed, Inc.$351
  • Shionogi Inc$156
  • Merck$115
  • La Jolla Pharmaceutical Company$96
  • plus $389 from 9 others

What the payments were for

  • Food & beverage$2,25397%
  • Education$603%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,313 in reported general payments places this provider in the 75th percentile of 51 infectious disease providers in Oklahoma.

See all infectious disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$798,976
Medicare patients
722
Services billed
371,417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala251$1,002,149
TriumeqAbacavir/Dolutegravir/Lamivudi89$345,108
Daptomycin412$205,248
TivicayDolutegravir Sodium41$109,150
DescovyEmtricitabine/Tenofov Alafenam36$91,076
IsentressRaltegravir Potassium39$75,351
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$47,520
ErtapenemErtapenem Sodium116$41,520
CompleraEmtricita/Rilpivirine/Tenof Df12$41,499
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df24$40,793
Vancomycin Hcl220$37,244
Darunavir43$28,429
Efavirenz29$20,459
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam78$14,754
Cefazolin Sodium148$13,300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$638$1,140,746299 claims
Viiv Healthcare CompanyTriumeq, Tivicay$568$454,258130 claims
MerckIsentress$115$75,35139 claims
Johnson & JohnsonComplera$16$41,49912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 51 infectious disease providers in Oklahoma.

Other infectious disease in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →